HOSPIRA, INC. for HOSPIRA INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 20, 2015 | $390,000 | Replaced |
| 1st Quarter - Amendment (this page) | Jan 20, 2016 | $380,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Implementation of the Biologics Price Competition and Innovation Act (BPCIA)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIANA REED | — |
| WENDY SUSSMAN | — |
Medicare/Medicaid MMM
Working to ensure that issues related to coding and reimbursement are discussed and addressed to ensure a smooth start to the coverage of biosimilar medications as they enter into the United States' prescription drug market this year.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIANA REED | — |
| WENDY SUSSMAN | — |
Pharmacy PHA
Issues related to the naming of biosimilars as they enter into the national prescription drug marketplace; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIANA REED | — |
| WENDY SUSSMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.